Belvedere Trading
XERS icon

Belvedere Trading’s Xeris Biopharma Holdings XERS Stock Holding History

Belvedere Trading’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-47,282
Closed -$103K – 651
2021
Q4 		$103K Buy
+47,282
New +$102K ﹤0.01% 294

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's XERS Position: Q1 2022 in Review

Belvedere Trading sold out of Xeris Biopharma Holdings (XERS) in Q1 2022, closing a stake of 47,282 shares — an estimated $103K sold.

Belvedere Trading first reported a position in XERS in Q4 2021 and held it in 1 quarter. The position peaked at $103K in Q4 2021. 103 funds tracked by Wall St. Rank hold XERS as of Q1 2022.

  • Belvedere Trading reported no remaining Xeris Biopharma Holdings position as of Q1 2022 after selling out during the quarter.
  • Belvedere Trading sold 47,282 Xeris Biopharma Holdings shares in Q1 2022, an estimated $103K.
  • Belvedere Trading first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 1 quarter.
  • Belvedere Trading's Xeris Biopharma Holdings position peaked at $103K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2022.

Based on Belvedere Trading's 13F filing for Q1 2022, filed 20 Apr 2022.